A Trial on Ophthalmologist-delivered Health Education on Top of Routine Community Care
2022年2月8日 更新者:Zhongshan Ophthalmic Center, Sun Yat-sen University
The Effectiveness of Ophthalmologist-delivered Health Education on Top of Routine Community Care in Type 2 Diabetic Patients at Risk for Diabetic Retinopathy: A Parallel-group, Randomised Trial
Diabetic retinopathy affects over one third of all people with diabetes and is one of the leading causes of vision loss.
The management of diabetes and its complications should include screening for diabetic retinopathy.
A randomised trial is therefore needed of the use of a simple and widely practicable approach to explore the integration of eye care in managing diabetes.
The trial is designed as a randomised, controlled, superiority trial.
The aim is to explore the effectiveness of ophthalmologist-delivered health education on top of routine community care on blood glucose and eye-related clinical outcomes in type 2 diabetic patients at risk for diabetic retinopathy.
調査の概要
詳細な説明
Diabetic retinopathy (DR) is a highly specific vascular complication of diabetes mellitus, with prevalence strongly related to a number of risk factors including the duration of diabetes, the level of glycaemic control, etc. Diabetic retinopathy affects over one third of all people with diabetes and is one of the leading causes of vision loss.
It is recommended that optimising glycaemic control could reduce the risk or slow the progression of diabetic retinopathy, and that the management of diabetes and its complications should include screening for diabetic retinopathy.
A randomised trial is therefore needed of the use of a simple and widely practicable approach to explore the integration of eye care in managing diabetes.
The trial is designed as a randomised, controlled, superiority trial.
The aim is to explore the effectiveness of ophthalmologist-delivered health education on top of routine community care on blood glucose and eye-related clinical outcomes in type 2 diabetic patients at risk for diabetic retinopathy.
Participants will be randomly assigned to either control or intervention group with a 1:1 allocation as per computer-generated random numbers.
A senior onsite manager will monitor participant enrolment over the course of the study.
An ophthalmologist-delivered health education will be offered as the intervention in an individualised, face-to-face counselling session to build awareness on diabetes symptoms, particularly on diabetic retinopathy, and its risk factors with appropriate management.
All subjects, regardless of the group allocation, will be followed up for 12 months.
Baseline and follow-up profiles will be assessed and collected by clinical personnel blind to group allocation.
The intervention arm will be compared against the control for all primary analysis.
The study was partly supported by the Open Research Funds of the State Key Laboratory of Ophthalmology.
Trial results will be disseminated to key stakeholders and the general medical community.
研究の種類
介入
入学 (予想される)
652
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Yuting LI, MPH
- 電話番号:+86-020-87334687
- メール:liyuting@gzzoc.com
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510000
- 募集
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
コンタクト:
- Yuting LI, MPH
- 電話番号:+86-020-87334687
- メール:liyuting@gzzoc.com
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
35年~80年 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Age 35-80 years
- Clinically diagnosed with type 2 diabetes
- At risk of diabetic retinopathy (DR),e.g. no apparent DR or mild non-proliferative DR
- On regular community care by 'family doctor team' in the context of the National basic public health service delivery
Exclusion Criteria:
- With symptoms of cognitive dysfunction, dementia, severe mental disorders, or other conditions with inability to appropriately convey personal thoughts
- Type 1 diabetes or gestational diabetes
- Developed with eye conditions requiring timely treatment, e.g., diabetic macular edema, severe non-proliferative diabetic retinopathy, or proliferative DR
- Have a family member (including relatives) who participated in the trial with a different group assignment
- Currently enrol in other ongoing interventions that may exert additional effects on blood glucose control
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:介入群
|
The educational intervention will be conducted on-site by a qualified, experienced ophthalmologist at an ophthalmic center with goals of building awareness on diabetes symptoms, particularly on diabetic retinopathy, and its risk factors with appropriate management.
|
|
他の:対照群
|
Usual care follows standard procedure on diabetes management similar to the routine service provision.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Glycated haemoglobin (HbA1c)
時間枠:12-months follow-up
|
Proportion of participants who had optimal control of HbA1c level at 12 months
|
12-months follow-up
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment burden
時間枠:12-months follow-up
|
Use of treatment burden questionnaire to quantify item scores for each domain, in detail and together, on treatment burden of patients
|
12-months follow-up
|
|
Patients' adherence
時間枠:12-months follow-up
|
Use of adherence questionnaire to examine the extent to which physician advice, in detail and together, are adhered to by patients
|
12-months follow-up
|
|
Body mass index
時間枠:12-months follow-up
|
Use of weight and height to report body mass index in kg/m^2
|
12-months follow-up
|
|
Blood pressure
時間枠:12-months follow-up
|
Use of systolic and diastolic blood pressure to report blood pressure profile in mmHg
|
12-months follow-up
|
|
cholesterol concentration
時間枠:12-months follow-up
|
Use of cholesterol concentration to report lipid profile in mmol/L
|
12-months follow-up
|
|
triglyceride concentration
時間枠:12-months follow-up
|
Use of triglyceride concentration to report lipid profile in mmol/L
|
12-months follow-up
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2020年7月22日
一次修了 (予想される)
2024年12月31日
研究の完了 (予想される)
2024年12月31日
試験登録日
最初に提出
2020年7月22日
QC基準を満たした最初の提出物
2020年7月28日
最初の投稿 (実際)
2020年7月29日
学習記録の更新
投稿された最後の更新 (実際)
2022年2月10日
QC基準を満たした最後の更新が送信されました
2022年2月8日
最終確認日
2022年2月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。